Details
Structure visualisation
Entry information
| Complex | |
| AACDB_ID: | 3250 |
| PDBID: | 6XZU |
| Chains: | A_B |
| Organism: | Lama glama, Mus musculus |
| Method: | XRD |
| Resolution (Å): | 1.50 |
| Reference: | 10.4049/jimmunol.2000752 |
| Antibody | |
| Antibody: | hC3Nb1 Nanobody |
| Antibody mutation: | No |
| INN (Clinical Trial): | |
| Antigen | |
| Antigen: | murine complement C3b |
| Antigen mutation: | No |
| Durg Target: | |
Sequence information
Antibody
Chain: A
Mutation: NULL
| >6XZU_A|Chain A|nanobody hC3Nb1|Lama glama (9844) MQVQLVESGGGLVQAGGSLRLSCVVSGSTFSDYAMGWYRQAAGEQRELVAAIYSTGRTNYIDSVKGRFTISRDNAKTTVYLQMNSLKPEDTAVYYCNLLGATTMINTKWGQGTQVTVSSLEHHHHHH |
Antigen
Chain: B
Mutation: NULL
| >6XZU_B|Chain B|Complement C3|Mus musculus (10090) ANCFMQQSQEKINLNVRLDKACEPGVDYVYKTELTNIELLDDFDEYTMTIQQVIKSGSDEVQAGQQRKFISHIKCRNALKLQKGKKYLMWGLSSDLWGEKPNTSYIIGKDTWVEHWPEAEECQDQKYQKQCEELGAFTESMVVYGCPN |
Interaction
1、Solvent accessible surface areas (SASA) were calculated (Naccess V2.1.1) for each residue in antibody and antigen, respectively. The residues with SASA loss in binding of more than 1Å2 were classified as interacting residues.
Interacting residues (ΔSASA based)
| A: TYR33 ALA34 TYR38 LEU48 VAL49 ALA51 TYR53 SER54 THR55 ARG57 ASN59 TYR60 ILE61 LYS65 LEU98 LEU99 GLY100 THR102 THR103 MET104 ILE105 B: LEU1529 ASN1530 LEU1533 ALA1634 CYS1637 GLN1638 LYS1644 CYS1646 GLU1647 GLY1650 ALA1651 THR1653 GLU1654 SER1655 VAL1658 TYR1659 GLY1660 PRO1662 ASN1663 |
2、We defined interacting paratope-epitope residues by a distance cutoff of < 5Å . Two amino acids are considered as interacting residues if they have at least one atom within a distance of 5 Å from any atom.
Interacting residues (Atom distance based)
